Vivimed Labs. (VIVIMEDLAB)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Vivimed Labs is the kind of stock that looks cheap only if you stop at the balance sheet. At ₹6.85, it trades below a book value of ₹8.35, so the P/B is 0.82. But Ben Graham taught me that a discount to book is meaningless if the business keeps losing money. This company lost ₹7 crore on sales of ₹21 crore in the latest quarter. ROE is -34.27% and ROCE is -8.10%. The return on equity is deeply negative, meaning every rupee of book value invested is being burned. Sales are declining 16.79%, profits are declining 42.02%, and the Piotroski F-score is 2 out of 9. That is not a healthy business; it is a business in distress. I also notice promoter holding is just 7.77%. When promoters own that little, I ask myself: do they have the same incentive as outside shareholders to fix the business? The absence of dividend also means I won't be paid to wait. Debt-to-equity is not available, so I cannot fully assess the balance-sheet risk. A P/E of zero is not attractive—it is just a sign that earnings are absent. The current price may be near the bottom of the 52-week range, and market cap of ₹63 crore is small, but small is not always beautiful. If the company can stabilise sales and get back to breakeven, there could be an operational turnaround. Till I see evidence of that, I would treat this as a possible turnaround situation, not a value investment. I want to see sales stop falling, losses narrow, book value hold steady, and promoter stake increase. Without those signs, a cheap price can become cheaper. In Graham's words, price is what you pay, value is what you get. Here, value remains unproven.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer